| Literature DB >> 26751161 |
Guanglin Luo1, Ling Chen1, Catherine R Burton1, Hong Xiao1, Prasanna Sivaprakasam1, Carol M Krause1, Yang Cao1, Nengyin Liu1, Jonathan Lippy1, Wendy J Clarke1, Kimberly Snow1, Joseph Raybon1, Vinod Arora1, Matt Pokross1, Kevin Kish1, Hal A Lewis1, David R Langley1, John E Macor1, Gene M Dubowchik1.
Abstract
GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimer's disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, we present a class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26751161 DOI: 10.1021/acs.jmedchem.5b01550
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446